Mankind Pharma IPO Particulars & Guidance @ Chanakyanipothi.com, India`s Oldest & the most Trusted Investment website for coming up IPOs. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years.
Mankind IPO listing at which price? The scrip will list on 9th May 2023. The grey market of the IPO witnessed sharp volatility. At one time the GMP had declined to Zero and there were no trades seen and then suddenly the GMP shot up to Rs. 73 and gradually improved to current level of Rs. 100/103. However, the traders show complete uncertainty about listing price. The way the promoters are Expert & energetic about the marketing, promotions and new launches, we expect positive listing, not just Rs. 1200, but there are all chances that on listing day, the scrip moves up to Rs. 1400 and yet there are large number of investors and traders who are skeptical of listing. They fear negative listing.
Actual Listing: The scrip listed at Rs. 1300 and during the intraday, it moved up to Rs. 1393.65
Whether you should apply in Mankind Pharma IPO?
The management has formed habit of very fast and impressive growth. Highly capable of developing strong brands in Pharma and FMCG businesses. Grown organically and is the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in the Financial Year 2022. At a first glance, the price may appear to be high, grey market fancy is also not so strong and yet, the IPO is very very reasonably price and will bring in impressive returns if you remain invested for 9 months.
Apply with full force.
Listing gains are also expected.
Who are the Anchor Investors of Mankind Pharma?
Mankind Pharma raised Rs 1,298 crore from 77 anchor investors.
The marquee investors that participated in the offer included Canada Pension Plan, Government of Singapore, Monetary Authority of Singapore, Goldman Sachs, Fiam Group Trust, Blackrock Global Funds, Abu Dhabi Investment Authority, Nomura Funds, Morgan Stanley, and Neuberger Berman Emerging Markets Equity Fund. HDFC Trustee, SBI Mutual Fund, Fidelity Investment, Motilal Oswal Mutual Fund, Nippon Life India, Axis Mutual Fund, Kotak Mutual Fund, Aditya Birla Sun Life Trustee, Franklin India, ICICI Prudential Life Insurance, HDFC Life Insurance, SBI Life Insurance, Tata Mutual Fund, and Kotak Mahindra Life Insurance also made an investment in the company via anchor book.
What is the current grey market premium for Mankind Pharma IPO ?
On Thursday, the grey market swung into action with GMP of Rs. 33 and within few minutes, the premium moved up to Rs. 40 and now on Friday, the GMP has shot up to Rs.100. Strong volume is seen for Retail Kostak and subject to.
Rs.2 L application Rs. 9,000, (No trades)
Rs. 10 L applications Rs. 12000 (No Trades)
What is the Subscription Status Mankind Pharma IPO?
On 27 April 2023 @ 5.00 (Closed)
QIB 8011769 Shares, 49.16T
NII: 6008827 Shares 3.80T
RII: 14020596 Shares 0.92T
Total: 28041192 Shares 15.32T
Who are the promoters of Mankind Pharma?
RAMESH JUNEJA, RAJEEV JUNEJA, SHEETAL ARORA, RAMESH JUNEJA FAMILY TRUST, RAJEEV JUNEJA FAMILY TRUST AND PREM SHEETAL FAMILY TRUST
Mankind Pharma IPO Particulars & Guidance
Very Elaborate Business Information:
Mankind Pharma is India’s fourth largest pharmaceutical company in terms of Domestic Sales and second largest in terms of sales volume for the Financial Year 2022. It is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It is focused on the domestic market, as a result of which its revenue from operations in India contributed to 97.60% of its total revenue from operations for the Financial Year 2022, which was one of the
highest among peers identified by IQVIA.
It has primarily grown organically and are the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in the Financial Year 2022.It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. It has created 36 brands in its pharmaceutical business that have each achieved over Rs 500.00 million in Domestic Sales in the Financial Year 2022.
It has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market and over 80% of doctors in India prescribed its formulations during the Financial Year 2022, which has assisted it in establishing its brands in India. Its brands have enabled it to consistently generate the highest share of drug prescriptions in the IPM over the last five years. Further, in its Covered Markets, it was ranked second by market share for the Financial Year 2022.
Mankind has experienced sustained growth and have consistently outperformed the growth of the IPM. Between the Financial Years 2020 and 2022, its Domestic Sales grew at a CAGR of approximately 16% from approximately Rs 60,647 million to approximately Rs 82,198 million, which is approximately 1.5 times that of the IPM, which grew at a CAGR of approximately 11%.
Between the Financial Years 2020 and 2022, its Domestic Sales had the fastest growth (at a CAGR of
approximately 16%) among the 10 largest corporates in the IPM by Domestic Sales. Its Domestic Sales ranking in the IPM improved from 8th in the Financial Year 2012 to 4th in the Financial Year 2022
Its consistent growth has been backed by its capital efficiency, and it had RoCE of 35.86%, 30.41% and 25.50% for the Financial Years 2020, 2021 and 2022, respectively.
Mankind Pharma is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients and respiratory.
The company has made efforts to establish “Mankind” as a well-recognized brand in India. It has a demonstrated track record of creating brands with Domestic Sales of over Rs 1.00 billion and had the third highest number of such brands for any company in the IPM as of March 31, 2022.
Mankind has a pan-India marketing presence, with a field force of 11,196 medical representatives and 3,195 field managers, as of March 31, 2022. It has also established a significant distribution network in India, and, during the Financial Year 2022, it sold its products to over 11,000 stockists and engaged with 75 C&F agents.
The company operates 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022.
Its formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022. Several of the facilities have obtained approvals or certifications from, and are subject to inspections by, a range of regulatory bodies including the CDSCO and the USFDA.
Through its R&D capabilities, it has developed a portfolio of differentiated products across several therapeutic areas. As of March 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with three units located in IMT Manesar, Gurugram, Haryana. One unit of
this R&D center is recognized by the DSIR, and one unit is in compliance with WHO GMP and has been inspected by the USFDA.
For more information, click www.mankindpharma.com
Mankind Pharma IPO DRHP
What are the Objects of Mankind Pharma IPO?
This is only an offer for sale of Shares by the selling shareholders.
|Mankind Pharma IPO Details|
|IPO opens on||25 April ,2023|
|IPO closes on||27 April ,2023|
|Issue Type||Book Built Issue IPO|
|Issue Size||40,058,844 Sh /Rs 4326.36 Cr|
|* Fresh Issue||– Sh /Rs – Cr|
|* Offer for Sale||40,058,844 Sh /Rs 4326.36 Cr|
|Face Value per share:||Rs. 1|
|What is the Price Band of Mankind Pharma IPO?||Rs. 1026-1080|
|Retail Discount||Rs 0 per share|
|Employee discount||Rs. 0 per share|
|Retail Lot Size||13 Shares|
|Listing will at||BSE, NSE|
|Shares offered to||Shares||Rs. in Cr|
|QIB (50 %)||20029422||2163.18|
|NII (15 %)||6008827||648.96|
|RII (35 %)||14020595||1514.22|
|Retail portion will be oversubscribed by||1078507 Forms.|
|How to Apply in Mankind Pharma IPO?||Amount
|Min Retail Application||13 Sh||Rs. 14040|
|Max Retail Application||182 Sh||Rs. 196560|
|Small HNI (Min) application||195 Sh||Rs. 210600|
|Small HNI (Max) application||923 Sh||Rs. 996840|
|Big HNI Application||936 Sh||Rs. 1010880|
Mankind Pharma IPO Particulars & Guidance
|Mankind Pharma IPO Tentative timetable|
|IPO opens on||25 April 2023|
|IPO Closes on||27 April 2023|
|IPO Allotment on||3 May 2023|
|Unblocking of ASBA||4 May 2023|
|Credit of Shares||5 May 2023|
|Listing on||9 May 2023|
|Registered Office of the Company
208, Okhla Industrial Estate, Phase-III, New Delhi 110 020, Delhi, India
|Who are the lead managers of Mankind Pharma IPO?
Kotak Mahindra Capital Company, Axis Capital Limited, IIFL Securities Limited, Jefferies India Private Limited, J.P. Morgan India
|Who is the Registrar Mankind Pharma IPO?|
|KFin Technologies Limited|
|Mankind Pharma IPO Financial & Analytical Ratios|
|Year||Total Income||Net Profit||EPS||RoE|
|Rs. in Cr||Rs.in Cr||Rs.||%|
|Book Value of the Share on||31.03.2022||Rs. 153.65|
|Book Value of the Share||after the FPO||Rs.178.38|
|Offer Price at Cap||Rs. 1080|
|Key Performance Indicators of Mankind Pharma IPO|
|Upper Price /last EPS||30.18|
|Upper Price/Book Value Ratio||7.03|
|Upper Price/BV after IPO||6.05|
Mankind Pharma IPO Particulars & Guidance
|As on date of DRHP||FV||Total||PE|
|Rs. In Cr|
|The IPO Company||1||7782||30.18|
|Procter & Gamble Health||10||11,144||42.27|
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
What is the latest Grey market premium and Subject to rates for Mankind Pharma IPO?
Click latest updates.
>>Go to SME IPOs Section: Click
>>Get Good Staff or Job, Click: Staffavailable.com
>>Interested in Used Automobiles or vintage cars? Click: BigGaddi.com
>>Get solid Guidance on Mutual fund Investments, Click: ChanakyaMFGuidance.com
>>Study Stock Research Reports, Click: AnalysisLibrary.com
>>Interested in Crossword Puzzles? Click: Magajmari.com
Listing on 9th MAY,
Please update in your details.
Not listed today.
Fully Priced ho chahe. Lekin Grey market mein Majboot hai. Aur Grey market se kisi Operators ne hi maal uthaya hai.
Listing ke din ₹1250 jaroor dikhayega.
It’s fully priced.
May buy after some time after listing.
Prices of this share could have been less. Although performance is good, as usual it is highly priced when compared with other peers. We all feel that there’s little room for the investors to earn after listed